Top

Published in:

Open Access 01-12-2021 | Multiple Sclerosis | Case report

Acute posterior reversible encephalopathy syndrome (PRES) in setting of interferon-beta use: case presentation with reduction of edema in 72 h after cessation of interferon-beta therapy with sub-clinical inflammation

Authors: Nicholas Dietz, Zarmina Mufti, Muhammed Yousaf, Randal Brown, Christopher Counts, Martin F. Bjurström, Brian J. Williams, David Robertson

Published in: BMC Neurology | Issue 1/2021

Abstract

Background

Posterior reversible encephalopathy syndrome (PRES) represents a transient change in mental status with associated vasogenic edema of cortical and subcortical brain structures. It is often attributed to multifactorial etiology including hypertension and altered hemodynamics and disruption of vessel integrity. Patients with autoimmune disease and certain immune modulator therapies are at greater risk.

Case presentation

A 54-year-old female with past medical history of well-controlled multiple sclerosis on interferon-beta since 2013, presented with witnessed tonic colonic seizure. She also was noted to demonstrate left gaze deviation and left-sided hemiparesis. MRI fluid-attenuated inversion recovery sequence showed hyperintensity of the subcortical U fibers, concentrated in the occipital, parietal lobes and frontal lobes. Systolic blood pressure was 160 mmHg on arrival. The patient was started on seizure prophylxis and Interferon beta was discontinued. The patient’s mentation, seizures and hemiapresis significantly improved in next 72 h with tight blood pressure control, and had notble improvement on MRI imaging and inflammatory markers. Lumbar puncture CSF results were devoid of infectious and autoimmune pathology.

Conclusions

A middle-aged female with multiple sclerosis who was on chronic IFN-beta presented to the emergency room with a witnessed tonic-clonic seizure, with MRI T2 FLAIR imaging consistent with PRES. She had notable clinical improvement with decreased edema on imaging and improved inflammatory markers 72 h after cessation of IFN-beta therapy.

Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14:914–25. https://doi.org/10.1016/S1474-4422(15)00111-8.CrossRefPubMed

Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500. https://doi.org/10.1056/NEJM199602223340803.CrossRefPubMed

Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int. 2012;32:590–4. https://doi.org/10.3747/pdi.2012.00152.CrossRefPubMedPubMedCentral

Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017;264:1608–16. https://doi.org/10.1007/s00415-016-8377-8.CrossRefPubMedPubMedCentral

Fugate JE, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32. https://doi.org/10.4065/mcp.2009.0590.CrossRefPubMedPubMedCentral

Rabinstein AA, et al. Blood pressure fluctuations in posterior reversible encephalopathy syndrome. J Stroke Cerebrovasc Dis. 2012;21:254–8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.03.011.CrossRefPubMed

Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65:205–10. https://doi.org/10.1001/archneurol.2007.46.CrossRefPubMed

Roth C, Ferbert A. The posterior reversible encephalopathy syndrome: what's certain, what's new? Pract Neurol. 2011;11:136–44. https://doi.org/10.1136/practneurol-2011-000010.CrossRefPubMed

Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol. 2006;27:2179–90.PubMedPubMedCentral

10.

Marra A, et al. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses. 2014;82:619–22. https://doi.org/10.1016/j.mehy.2014.02.022.CrossRefPubMed

11.

Kou R, Greif D, Michel T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin a. J Biol Chem. 2002;277:29669–73. https://doi.org/10.1074/jbc.M204519200.CrossRefPubMed

12.

Mastorodemos VC, Ioannidis SG, Papadaki EZ, Mitsias PD. Posterior reversible encephalopathy syndrome, multiple sclerosis and interferon therapy: association, co-incidence or convoluted interplay? Mult Scler Relat Disord. 2020;45:102356. https://doi.org/10.1016/j.msard.2020.102356.CrossRefPubMed

13.

Oxford BG, Khattar NK, Adams SW, Schaber AS, Williams BJ. Posterior reversible encephalopathy syndrome with lumbar drainage and surgery: coincidence or correlation? A case report. BMC Neurol. 2019;19:214. https://doi.org/10.1186/s12883-019-1438-8.CrossRefPubMedPubMedCentral

14.

Pirker A, et al. Type of edema in posterior reversible encephalopathy syndrome depends on serum albumin levels: an MR imaging study in 28 patients. AJNR Am J Neuroradiol. 2011;32:527–31. https://doi.org/10.3174/ajnr.A2332.CrossRefPubMedPubMedCentral

15.

Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Interferon beta for multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8. https://doi.org/10.1101/cshperspect.a032003.

16.

Plosker GL. Interferon-beta-1b: a review of its use in multiple sclerosis. CNS Drugs. 2011;25:67–88. https://doi.org/10.2165/11206430-000000000-00000.CrossRefPubMed

17.

Allinovi M, et al. Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. Clin Kidney J. 2017;10:625–31. https://doi.org/10.1093/ckj/sfw143.CrossRefPubMedPubMedCentral

18.

Kavanagh D, et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood. 2016;128:2824–33. https://doi.org/10.1182/blood-2016-05-715987.CrossRefPubMedPubMedCentral

19.

Gao B, Liu FL, Zhao B. Association of degree and type of edema in posterior reversible encephalopathy syndrome with serum lactate dehydrogenase level: initial experience. Eur J Radiol. 2012;81:2844–7. https://doi.org/10.1016/j.ejrad.2011.12.010.CrossRefPubMed

20.

Chen Z, Shen GQ, Lerner A, Gao B. Immune system activation in the pathogenesis of posterior reversible encephalopathy syndrome. Brain Res Bull. 2017;131:93–9. https://doi.org/10.1016/j.brainresbull.2017.03.012.CrossRefPubMed

21.

Siebert E, Bohner G, Liebig T, Endres M, Liman TG. Factors associated with fatal outcome in posterior reversible encephalopathy syndrome: a retrospective analysis of the Berlin PRES study. J Neurol. 2017;264:237–42. https://doi.org/10.1007/s00415-016-8328-4.CrossRefPubMed

22.

Feske SK. Posterior reversible encephalopathy syndrome: a review. Semin Neurol. 2011;31:202–15. https://doi.org/10.1055/s-0031-1277990.CrossRefPubMed

23.

Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28:1320–7. https://doi.org/10.3174/ajnr.A0549.CrossRefPubMedPubMedCentral

24.

Ellis CA, et al. Cerebrospinal fluid in posterior reversible encephalopathy syndrome: implications of elevated protein and Pleocytosis. Neurohospitalist. 2019;9:58–64. https://doi.org/10.1177/1941874418802061.CrossRefPubMed

Title: Acute posterior reversible encephalopathy syndrome (PRES) in setting of interferon-beta use: case presentation with reduction of edema in 72 h after cessation of interferon-beta therapy with sub-clinical inflammation
Authors: Nicholas Dietz
Zarmina Mufti
Muhammed Yousaf
Randal Brown
Christopher Counts
Martin F. Bjurström
Brian J. Williams
David Robertson
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Multiple Sclerosis
Edema
Hypertension
Interferon
Posterior Reversible Encephalopathy Syndrome
Hypertension
Published in: BMC Neurology / Issue 1/2021
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02471-7

2024 ASCO Annual Meeting

Springer Medicine

Acute posterior reversible encephalopathy syndrome (PRES) in setting of interferon-beta use: case presentation with reduction of edema in 72 h after cessation of interferon-beta therapy with sub-clinical inflammation

Abstract

Background

Case presentation

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Atypical presentation of Charcot-Marie-Tooth disease type 1C with a new mutation: a case report

The clinical and prognostic values of optic nerve sheath diameter and optic nerve sheath diameter/eyeball transverse diameter ratio in comatose patients with supratentorial lesions

Critical issue on the extinction and inattention subtest of NIHSS scale: an analysis on post-acute stroke patients attending inpatient rehabilitation

Nerve transfer surgery in spinal cord injury: online information sharing

Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements

Innumerable cerebral microbleeds in hepatitis B virus-related decompensated liver cirrhosis: a case report